Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 6/2016

01-06-2016 | Original Article

Miscarriage and recurrent miscarriage in patients with congenital factor V deficiency: a report of six cases in Iran

Authors: Majid Naderi, Shadi Tabibian, Morteza Shamsizadeh, Akbar Dorgalaleh

Published in: International Journal of Hematology | Issue 6/2016

Login to get access

Abstract

Miscarriage and recurrent miscarriage have not been reported in women with congenital factor V (FV) deficiency. Here we describe cases of both miscarriage and recurrent miscarriage in women with congenital FV deficiency (FVD). We investigated six women with FVD from the southeast of Iran who had experienced miscarriage and recurrent miscarriage. Consequent diagnosis was made by routine coagulation tests as well as FV activity and antigen assays. To evaluate the presence of an inhibitor, a mixing study via prothrombin time (PT) assay was performed. All patients were investigated, and found to be negative for antiphospholipid syndrome. Demographic data and clinical presentations were obtained by standard questionnaire. The factor assays determined that all six women were suffering from moderate FVD. One had experienced eight miscarriages, while the others experienced two (two patients), three, and four episodes. Only one patient had a single miscarriage. Three of the women experienced successful delivery without medical intervention. Miscarriage and recurrent miscarriage should be considered as possible presentations of FVD to prevent its life-threatening consequences.
Literature
1.
2.
Naderi M, Tabibian S, Hosseini MS, Alizadeh S, Hosseini S, Shamsizadeh M, et al. Congenital combined deficiency of coagulation factors: a study of seven patients. Blood Coagul Fibrinolysis. 2015;26(1):59–62.CrossRefPubMed
3.
Naderi M, Tabibian S, Hosseini MS, Alizadeh S, Hosseini S, Karami H, et al. Rare bleeding disorders: a narrative review of epidemiology, molecular and clinical presentations, diagnosis and treatment. J Pediatr Rev. 2014;2(2):31–46.
4.
Naderi M, Tabibian S, Dorgalaleh A, Kashani Kahtib Z, Alizadeh S. Public health problems related to factor V deficiency in southeast of Iran. Med J Islam Repub Iran. 2014;28(1):171–3.
5.
Naderi M, Tabibian S, Alizadeh S, Hosseini S, Zaker F, Bamedi T, et al. Congenital factor V deficiency: comparison of the severity of clinical presentations among patients with rare bleeding disorders. Acta Haematol. 2014;133(2):148–54.CrossRefPubMed
6.
SanneVellinga ES, IngeVangenechten AG. Successful pregnancy in a patient with factor V deficiency: case report and review of the literature. Thromb Haemost. 2006;95:896–7.
7.
Girolami A, Scandellari R, Lombardi A, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. Haemophilia. 2005;11(1):26–30.CrossRefPubMed
8.
Dorgalaleh A, Naderi M, Hosseini MS, Alizadeh S, Hosseini S, Tabibian S, et al. Factor XIII deficiency in Iran: a comprehensive review of the literature. Semin Thromb Hemost. 2015;41(3):323–9.CrossRefPubMed
9.
Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Hosseini MS, et al. Clinical manifestations and bleeding episodes among heterozygote individuals of factor XIII deficiency, a short term prospective study. Blood. 2014;124(21):2852.
10.
Naderi M, Dorgalaleh A, Alizadeh S, Tabibian S, Hosseini S, Shamsizadeh M, et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol. 2014;100(5):443–9.CrossRefPubMed
11.
Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol. 2016;95(3):451–5.CrossRefPubMed
12.
13.
O’Connell M, Eogan M, Murphy K, White B, Keane D, O’Donnell J. Solvent–detergent plasma as replacement therapy in a pregnant patient with factor V deficiency. J Matern-Fetal Neonatal Med. 2004;16(1):69–70.CrossRefPubMed
14.
Naderi M, Reykande SE, Dorgalaleh A, Alizadeh S, Tabibian S, Einollahi N, et al. Establishment of a prenatal diagnosis schedule as part of a prophylaxis program of factor XIII deficiency in the southeast of Iran. Blood Coagul Fibrinolysis. 2016;27(1):97–100.CrossRefPubMed
Metadata
Title
Miscarriage and recurrent miscarriage in patients with congenital factor V deficiency: a report of six cases in Iran
Authors
Majid Naderi
Shadi Tabibian
Morteza Shamsizadeh
Akbar Dorgalaleh
Publication date
01-06-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 6/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-1981-7

Other articles of this Issue 6/2016

International Journal of Hematology 6/2016 Go to the issue

Original Article

A comparative analysis of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria between Asia and Europe/America

Original Article

Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review

Original Article

Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors

Original Article

Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04)

Progress in Hematology

DNA methylation in normal and malignant hematopoiesis

Case Report

Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroids
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits